Candida News and Research RSS Feed - Candida News and Research

Scientists discover protein structure that helps common fungal pathogen to infect humans

Scientists discover protein structure that helps common fungal pathogen to infect humans

A team that includes scientists from the School of Medicine at The University of Texas Health Science Center at San Antonio, Johns Hopkins University and St. Mary's University reported the structure of a protein that helps a common fungus to infect the body. [More]
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. [More]
Study shows effect of oral fungal yeast in inhibiting thrush

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida. [More]
Bacterium and fungus partner to cause painful form of tooth decay in preschool children

Bacterium and fungus partner to cause painful form of tooth decay in preschool children

Early childhood caries, a highly aggressive and painful form of tooth decay that frequently occurs in preschool children, especially from backgrounds of poverty, may result from a nefarious partnership between a bacterium and a fungus, according to a paper published ahead of print in the journal Infection and Immunity. [More]
Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

The gut microbiota contains a vast number of microorganisms from all three domains of life, including bacteria, archaea and fungi, as well as viruses. These interact in a complex way to contribute towards both health and the development of disease - interactions that are only now being elucidated thanks to the application of advanced DNA sequencing technology in this field. [More]
Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds. [More]

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Led by University of Melbourne PhD candidate Cathy Watson also of the Royal Women's Hospital, the findings were published online in the British Journal of Obstetrics and Gynaecology. [More]
Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens. [More]

Oral garlic does not reduce vaginal thrush, study finds

In a world-first study, led by the University of Melbourne and the Royal Women’s Hospital, researchers have found garlic does not significantly reduce vaginal candida (thrush). [More]
IBN and IBM discover new medical application for converted PET bottles

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles. [More]
New material effective in destroying drug-resistant fungi

New material effective in destroying drug-resistant fungi

Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research – Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles. [More]
FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. [More]
Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. [More]

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration. [More]

Concordia University professors use funds to fight fungus and update aircraft

​Thanks to new funding from the Government of Canada, two Concordia University professors just might create a greener aerospace industry and help cure fungal infections. [More]
Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood. [More]
3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). [More]

Study shows how deadly Candida albicans might be rendered harmless

Candida albicans is a double agent: In most of us, it lives peacefully, but for people whose immune systems are compromised by HIV or other severe illnesses, it is frequently deadly. Now a new study from Johns Hopkins and Harvard Medical School shows how targeting a specific fungal component might turn the fungus from a lion back into a kitten. [More]

Microbiologist finds breakthrough herbal medicine treatment for common human fungal pathogen

A Kansas State University microbiologist has found a breakthrough herbal medicine treatment for a common human fungal pathogen that lives in almost 80 percent of people. [More]

New antibody could prevent Candida infections in patients who receive central lines

A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines. [More]